Showing results (251-260 of 302) with videos related to

Sort By:
Pageof 31
Blood|October 25, 2023
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Leukemia & Lymphoma|May 10, 2017
Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphomaJennifer C Ho, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Lancet. Oncology|December 13, 2021
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialCaron A Jacobson, Julio C Chavez, Alison R Sehgal, et al.
Blood Advances|May 12, 2019
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLLPaolo Strati, Koichi Takahashi, Christine B Peterson, et al.
JAMA Oncology|May 27, 2016
Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During PregnancyChelsea C Pinnix, Eleanor M Osborne, Dai Chihara, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2020
A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) LymphomaPenny Fang, Jillian R Gunther, Chelsea C Pinnix, et al.
Blood Advances|December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T ConsortiumMichael D Jain, Miriam T Jacobs, Feng Gao, et al.
Blood|May 20, 2017
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphomaMichelle A Fanale, Chan Yoon Cheah, Amy Rich, et al.
Lancet (London, England)|January 11, 2025
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trialArmin Ghobadi, Veronika Bachanova, Krish Patel, et al.
Pageof 31